Cocrystal Pharma soars on oral norovirus drug progress

Shares of drug developer Cocrystal Pharma COCP.O rise 80% to $2.59

Co at a conference says its lead oral drug, CDI-988, showed strong antiviral activity and a favorable safety profile, with high exposure in the small intestine

CDI-988 is being developed to treat and prevent norovirus infections, which cause stomach pain, vomiting, and diarrhea

As of last close, stock down 28.7% YTD